[{"id":"8fd9e0a5-26dd-43f5-b8b9-9671467c4e06","acronym":"","url":"https://clinicaltrials.gov/study/NCT00380029","created_at":"2021-01-24T05:54:01.526Z","updated_at":"2025-02-25T15:24:41.786Z","phase":"Phase 2","brief_title":"Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT00380029","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" AKT2","pipe":" | ","alterations":" AKT2 expression","tags":["AKT2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AKT2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 08/01/2010","primary_completion_date":" 08/01/2010","study_txt":" Completion: 06/01/2014","study_completion_date":" 06/01/2014","last_update_posted":"2017-07-19"}]